Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance.

Lienhardt C, Vernon AA, Cavaleri M, Nambiar S, Nahid P.

PLoS Med. 2019 Sep 6;16(9):e1002915. doi: 10.1371/journal.pmed.1002915. eCollection 2019 Sep.

2.

Multidrug-resistant tuberculosis - Authors' reply.

Menzies D, Benedetti A, Migliori GB, Nahid P, Seaworth B.

Lancet. 2019 Jul 27;394(10195):299-300. doi: 10.1016/S0140-6736(19)30692-0. No abstract available.

PMID:
31354139
3.

Feasibility of Direct Sputum Molecular Testing for Drug Resistance as Part of Tuberculosis Clinical Trials Eligibility Screening.

Alipanah N, Shete PB, Nguyen H, Nguyen NV, Luu L, Pham T, Nguyen H, Nguyen P, Tran MC, Pham N, Phan H, Phillips PPJ, Cattamanchi A, Nahid P.

Diagnostics (Basel). 2019 May 30;9(2). pii: E56. doi: 10.3390/diagnostics9020056.

4.

Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients.

Broger T, Tsionksy M, Mathew A, Lowary TL, Pinter A, Plisova T, Bartlett D, Barbero S, Denkinger CM, Moreau E, Katsuragi K, Kawasaki M, Nahid P, Sigal GB.

PLoS One. 2019 Apr 18;14(4):e0215443. doi: 10.1371/journal.pone.0215443. eCollection 2019.

5.

Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.

Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ.

PLoS Med. 2019 Mar 22;16(3):e1002767. doi: 10.1371/journal.pmed.1002767. eCollection 2019 Mar.

6.

Advances in clinical trial design for development of new TB treatments: A call for innovation.

Lienhardt C, Nahid P.

PLoS Med. 2019 Mar 22;16(3):e1002769. doi: 10.1371/journal.pmed.1002769. eCollection 2019 Mar.

7.

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2019 Jan;25(1):190. doi: 10.1038/s41591-018-0294-1.

PMID:
30429542
8.

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5. Erratum in: Nat Med. 2019 Jan;25(1):190.

9.

Moving toward Tuberculosis Elimination. Critical Issues for Research in Diagnostics and Therapeutics for Tuberculosis Infection.

Keshavjee S, Amanullah F, Cattamanchi A, Chaisson R, Dobos KM, Fox GJ, Gendelman HE, Gordon R, Hesseling A, Le Van H, Kampmann B, Kana B, Khuller G, Lewinsohn DM, Lewinsohn DA, Lin PL, Lu LL, Maartens G, Owen A, Protopopova M, Rengarajan J, Rubin E, Salgame P, Schurr E, Seddon JA, Swindells S, Tobin DM, Udwadia Z, Walzl G, Srinivasan S, Rustomjee R, Nahid P.

Am J Respir Crit Care Med. 2019 Mar 1;199(5):564-571. doi: 10.1164/rccm.201806-1053PP. No abstract available.

10.

A Novel Sensitive Immunoassay Targeting the 5-Methylthio-d-Xylofuranose-Lipoarabinomannan Epitope Meets the WHO's Performance Target for Tuberculosis Diagnosis.

Sigal GB, Pinter A, Lowary TL, Kawasaki M, Li A, Mathew A, Tsionsky M, Zheng RB, Plisova T, Shen K, Katsuragi K, Choudhary A, Honnen WJ, Nahid P, Denkinger CM, Broger T.

J Clin Microbiol. 2018 Nov 27;56(12). pii: e01338-18. doi: 10.1128/JCM.01338-18. Print 2018 Dec.

11.

The association between Cytomegalovirus co-infection with Pneumocystis pneumonia and mortality in immunocompromised non-HIV patients.

Korkmaz Ekren P, Töreyin ZN, Nahid P, Doskaya M, Caner A, Turgay N, Zeytinoglu A, Toz S, Bacakoglu F, Guruz Y, Erensoy S.

Clin Respir J. 2018 Nov;12(11):2590-2597. doi: 10.1111/crj.12961.

PMID:
30244544
12.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

13.

Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.

Kedia K, Wendler JP, Baker ES, Burnum-Johnson KE, Jarsberg LG, Stratton KG, Wright AT, Piehowski PD, Gritsenko MA, Lewinsohn DM, Sigal GB, Weiner MH, Smith RD, Jacobs JM, Nahid P.

Tuberculosis (Edinb). 2018 Sep;112:52-61. doi: 10.1016/j.tube.2018.07.005. Epub 2018 Jul 18.

14.

Does discovery of differentially culturable M tuberculosis really demand a new treatment paradigm? Longitudinal analysis of DNA clearance from sputum.

Walter ND, Moore CM, Kayigire XA, Dide-Agossou C, Worodria W, Huang L, Everett CK, Schoolnik GS, Nahid P, Davis JL.

BMC Infect Dis. 2018 Jul 3;18(1):293. doi: 10.1186/s12879-018-3213-7.

15.

Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies.

Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, Nahid P.

PLoS Med. 2018 Jul 3;15(7):e1002595. doi: 10.1371/journal.pmed.1002595. eCollection 2018 Jul.

16.

Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis.

Nahid P, Jarlsberg LG, Kato-Maeda M, Segal MR, Osmond DH, Gagneux S, Dobos K, Gold M, Hopewell PC, Lewinsohn DM.

PLoS One. 2018 May 22;13(5):e0195392. doi: 10.1371/journal.pone.0195392. eCollection 2018.

17.

Biomarkers of Tuberculosis Severity and Treatment Effect: A Directed Screen of 70 Host Markers in a Randomized Clinical Trial.

Sigal GB, Segal MR, Mathew A, Jarlsberg L, Wang M, Barbero S, Small N, Haynesworth K, Davis JL, Weiner M, Whitworth WC, Jacobs J, Schorey J, Lewinsohn DM, Nahid P.

EBioMedicine. 2017 Nov;25:112-121. doi: 10.1016/j.ebiom.2017.10.018. Epub 2017 Oct 24.

18.

Traffic-Related Air Pollution and All-Cause Mortality during Tuberculosis Treatment in California.

Blount RJ, Pascopella L, Catanzaro DG, Barry PM, English PB, Segal MR, Flood J, Meltzer D, Jones B, Balmes J, Nahid P.

Environ Health Perspect. 2017 Sep 29;125(9):097026. doi: 10.1289/EHP1699.

19.

Second generation multiple reaction monitoring assays for enhanced detection of ultra-low abundance Mycobacterium tuberculosis peptides in human serum.

Mehaffy C, Dobos KM, Nahid P, Kruh-Garcia NA.

Clin Proteomics. 2017 Jun 5;14:21. doi: 10.1186/s12014-017-9156-y. eCollection 2017.

20.

Clinical and bacteriological characteristics associated with clustering of multidrug-resistant tuberculosis.

Feng JY, Jarlsberg LG, Salcedo K, Rose J, Janes M, Lin SG, Osmond DH, Jost KC, Soehnlen MK, Flood J, Graviss EA, Desmond E, Moonan PK, Nahid P, Hopewell PC, Kato-Maeda M.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):766-773. doi: 10.5588/ijtld.16.0510. Epub 2017 May 16.

21.

Impact of Euro-American sublineages of Mycobacterium tuberculosis on new infections among named contacts.

Feng JY, Jarlsberg LG, Rose J, Grinsdale JA, Janes M, Higashi J, Osmond DH, Nahid P, Hopewell PC, Kato-Maeda M.

Int J Tuberc Lung Dis. 2017 May 1;21(5):509-516. doi: 10.5588/ijtld.16.0487.

PMID:
28399965
22.

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM.

Lancet Respir Med. 2017 Mar 15. pii: S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. [Epub ahead of print] Review.

PMID:
28344011
23.

First in vivo magnetic particle imaging of lung perfusion in rats.

Zhou XY, Jeffris KE, Yu EY, Zheng B, Goodwill PW, Nahid P, Conolly SM.

Phys Med Biol. 2017 May 7;62(9):3510-3522. doi: 10.1088/1361-6560/aa616c. Epub 2017 Feb 20.

24.

Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, Peloquin CA, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention.

Clin Pharmacol Ther. 2017 Aug;102(2):321-331. doi: 10.1002/cpt.634. Epub 2017 Mar 2.

25.

Target regimen profiles for treatment of tuberculosis: a WHO document.

Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M.

Eur Respir J. 2017 Jan 25;49(1). pii: 1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. No abstract available.

26.

Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW.

PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan.

27.

Vitamin D Deficiency in Patients Referred for Evaluation of Obstructive Sleep Apnea.

Salepci B, Caglayan B, Nahid P, Parmaksiz ET, Kiral N, Fidan A, Comert SS, Dogan C, Gungor GA.

J Clin Sleep Med. 2017 Apr 15;13(4):607-612. doi: 10.5664/jcsm.6554.

28.

Treatment of Drug-Susceptible Tuberculosis.

Dela Cruz CS, Lyons PG, Pasnick S, Weinstock T, Nahid P, Wilson KC, Thomson CC.

Ann Am Thorac Soc. 2016 Nov;13(11):2060-2063. No abstract available.

PMID:
27831799
29.

Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.

Jayakumar A, Savic RM, Everett CK, Benator D, Alland D, Heilig CM, Weiner M, Friedrich SO, Martinson NA, Kerrigan A, Zamudio C, Goldberg SV, Whitworth WC, Davis JL, Nahid P.

J Clin Microbiol. 2016 Dec;54(12):3028-3033. Epub 2016 Oct 12.

30.

Reply to Alffenaar et al.

Peloquin CA, Dorman SE, Vernon A, Battista Migliori G, Nahid P.

Clin Infect Dis. 2017 Jan 1;64(1):105-106. Epub 2016 Oct 26. No abstract available.

PMID:
27789610
31.

Treatment of non-cavitary pulmonary tuberculosis with shortened fluoroquinolone-based regimens: a meta-analysis.

Alipanah N, Cattamanchi A, Menzies R, Hopewell PC, Chaisson RE, Nahid P.

Int J Tuberc Lung Dis. 2016 Nov;20(11):1522-1528. Review.

PMID:
27776595
32.

Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):853-67. doi: 10.1093/cid/ciw566.

33.

The ERS-endorsed official ATS/CDC/IDSA clinical practice guidelines on treatment of drug-susceptible tuberculosis.

Sotgiu G, Nahid P, Loddenkemper R, Abubakar I, Miravitlles M, Migliori GB.

Eur Respir J. 2016 Oct;48(4):963-971. doi: 10.1183/13993003.01356-2016. Epub 2016 Sep 1. No abstract available.

34.

Tuberculosis progression rates in U.S. Immigrants following screening with interferon-gamma release assays.

Blount RJ, Tran MC, Everett CK, Cattamanchi A, Metcalfe JZ, Connor D, Miller CR, Grinsdale J, Higashi J, Nahid P.

BMC Public Health. 2016 Aug 25;16(1):875. doi: 10.1186/s12889-016-3519-6.

35.

Adaptation of Mycobacterium tuberculosis to Impaired Host Immunity in HIV-Infected Patients.

Walter ND, de Jong BC, Garcia BJ, Dolganov GM, Worodria W, Byanyima P, Musisi E, Huang L, Chan ED, Van TT, Antonio M, Ayorinde A, Kato-Maeda M, Nahid P, Leung AM, Yen A, Fingerlin TE, Kechris K, Strong M, Voskuil MI, Davis JL, Schoolnik GK.

J Infect Dis. 2016 Oct 15;214(8):1205-11. doi: 10.1093/infdis/jiw364. Epub 2016 Aug 17. Erratum in: J Infect Dis. 2017 Feb 1;215(3):495.

36.

Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A.

Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.

37.

Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Furin J, Alirol E, Allen E, Fielding K, Merle C, Abubakar I, Andersen J, Davies G, Dheda K, Diacon A, Dooley KE, Dravnice G, Eisenach K, Everitt D, Ferstenberg D, Goolam-Mahomed A, Grobusch MP, Gupta R, Harausz E, Harrington M, Horsburgh CR, Lienhardt C, McNeeley D, Mitnick CD, Nachman S, Nahid P, Nunn AJ, Phillips P, Rodriguez C, Shah S, Wells C, Thomas-Nyang'wa B, du Cros P.

Int J Tuberc Lung Dis. 2016 Mar;20(3):290-4. doi: 10.5588/ijtld.15.0490.

38.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

39.

Challenges in the clinical assessment of novel tuberculosis drugs.

Dooley KE, Phillips PP, Nahid P, Hoelscher M.

Adv Drug Deliv Rev. 2016 Jul 1;102:116-22. doi: 10.1016/j.addr.2016.01.014. Epub 2016 Jan 28. Review.

40.

A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.

Nicol MP, Gnanashanmugam D, Browning R, Click ES, Cuevas LE, Detjen A, Graham SM, Levin M, Makhene M, Nahid P, Perez-Velez CM, Reither K, Song R, Spiegel HM, Worrell C, Zar HJ, Walzl G.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S164-72. doi: 10.1093/cid/civ613.

41.

Evaluation of mobile digital light-emitting diode fluorescence microscopy in Hanoi, Viet Nam.

Chaisson LH, Reber C, Phan H, Switz N, Nilsson LM, Myers F, Nhung NV, Luu L, Pham T, Vu C, Nguyen H, Nguyen A, Dinh T, Nahid P, Fletcher DA, Cattamanchi A.

Int J Tuberc Lung Dis. 2015 Sep;19(9):1068-72. doi: 10.5588/ijtld.15.0018.

PMID:
26260826
42.

In vitro immunomodulation for enhancing T cell-based diagnosis of Mycobacterium tuberculosis infection.

Slater M, Tran MC, Platt L, Luu LT, Phan HT, Pham PT, Do TB, Nguyen HT, Gaur RL, Parsonnet J, Cattamanchi A, Luo R, Nahid P, Banaei N.

Diagn Microbiol Infect Dis. 2015 Sep;83(1):41-5. doi: 10.1016/j.diagmicrobio.2015.05.007. Epub 2015 May 19.

43.

Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis.

Jayakumar A, Vittinghoff E, Segal MR, MacKenzie WR, Johnson JL, Gitta P, Saukkonen J, Anderson J, Weiner M, Engle M, Yoon C, Kato-Maeda M, Nahid P; Tuberculosis Trials Consortium.

Tuberculosis (Edinb). 2015 Jul;95(4):415-20. doi: 10.1016/j.tube.2015.04.011. Epub 2015 May 9.

44.

Towards tuberculosis elimination: an action framework for low-incidence countries.

Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti D, González Ochoa ER, LoBue P, Matteelli A, Njoo H, Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D, Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S, Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM, Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM, Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P, Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J, Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C, Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K, Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ, Voniatis C, Wanlin M, Raviglione MC.

Eur Respir J. 2015 Apr;45(4):928-52. doi: 10.1183/09031936.00214014. Review.

45.

Transcriptional Adaptation of Drug-tolerant Mycobacterium tuberculosis During Treatment of Human Tuberculosis.

Walter ND, Dolganov GM, Garcia BJ, Worodria W, Andama A, Musisi E, Ayakaka I, Van TT, Voskuil MI, de Jong BC, Davidson RM, Fingerlin TE, Kechris K, Palmer C, Nahid P, Daley CL, Geraci M, Huang L, Cattamanchi A, Strong M, Schoolnik GK, Davis JL.

J Infect Dis. 2015 Sep 15;212(6):990-8. doi: 10.1093/infdis/jiv149. Epub 2015 Mar 11.

46.

Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M; Tuberculosis Trials Consortium.

Am J Respir Crit Care Med. 2015 Feb 1;191(3):333-43. doi: 10.1164/rccm.201410-1843OC. Erratum in: Am J Respir Crit Care Med. 2015 May 15;191(10):1210.

47.

Hepatotoxicity in Children Receiving Isoniazid Therapy for Latent Tuberculosis Infection.

Chang SH, Nahid P, Eitzman SR.

J Pediatric Infect Dis Soc. 2014 Sep;3(3):221-7. doi: 10.1093/jpids/pit089. Epub 2014 Jan 15.

PMID:
26625385
48.

Detection of Mycobacterium tuberculosis peptides in the exosomes of patients with active and latent M. tuberculosis infection using MRM-MS.

Kruh-Garcia NA, Wolfe LM, Chaisson LH, Worodria WO, Nahid P, Schorey JS, Davis JL, Dobos KM.

PLoS One. 2014 Jul 31;9(7):e103811. doi: 10.1371/journal.pone.0103811. eCollection 2014.

49.

Childhood tuberculosis in northern Viet Nam: a review of 103 cases.

Blount RJ, Tran B, Jarlsberg LG, Phan H, Thanh Hoang V, Nguyen NV, Lewinsohn DA, Nahid P.

PLoS One. 2014 May 12;9(5):e97267. doi: 10.1371/journal.pone.0097267. eCollection 2014.

50.

Non-tuberculous mycobacterial infections at San Francisco General Hospital.

Sheu LC, Tran TM, Jarlsberg LG, Marras TK, Daley CL, Nahid P.

Clin Respir J. 2015 Oct;9(4):436-42. doi: 10.1111/crj.12159. Epub 2014 Jun 10.

PMID:
24799125

Supplemental Content

Support Center